⌕
Pacira BioSciences · PCRX · Nasdaq
Tenet 56 · Mixed
Compare
$36.48+0.05%At closeTenet 56 · Mixed
$36.48+0.02 (+0.05%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Pacira BioSciences (PCRX) Stock

Pacira BioSciences (PCRX) closed at $36.48 on Nov 16, 2026; its Tenet Score is 56 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

6 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$36.48
Nov 16, 2026
Market cap
$1.5B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
39.5×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
18.80 – 36.66
low → high · as of close, Nov 17, 2026
Tenet Score
56/100
Mixed · 340 Healthcare peers

Industry: Drugs

Pacira BioSciences Inc scores 56/100. Mixed. Strongest on quality, trading at 39× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
56/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
62
Quality
68
Health
51
Growth
44

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityCHealthCGrowthDMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
2.1×
Sep 30, 2026 balance sheet
P/S
2.0×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
5%
TTM through Sep 30, 2026
Operating margin
2.6%
fiscal 2025, before interest and tax
Net margin
5.1%
TTM through Sep 30, 2026
Current ratio
4.68
Sep 30, 2026 balance sheet
Net debt / EBITDA
−0.0×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Pacira BioSciences Inc

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamc…

Composite computed Nov 17, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 108 US ETFs · top wrappers by weightSee all ETFs holding PCRX →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 17, 2026.

What sector and industry is Pacira BioSciences in?

Pacira BioSciences is in the Healthcare sector and the Drugs industry.

What is Pacira BioSciences' Tenet Score?

Pacira BioSciences' Tenet Score is 56 out of 100, ranked against 340 Healthcare peers as of Nov 17, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.